Abstract 11969: Complex Approach in the Decrease of Cardiovascular Risk in Daily Practice, the Varo Study
In the VARO study [V alsartan A mlodipin and RO suvastatin for global cardiovascular risk (CVR) decrease in daily practice], we verified the possibility of CVR improvement through systematic identification of high-risk individuals and treating in accordance with current guidelines using modern therapy in daily clinical practice.
Methods: 350 physicians participated in the study (68% GPs, 26% internists, 6% others). Individuals with hypertension and/or hyperlipidemia were included. The physicians were asked to screen for risk factors in patients presenting with unrelated problems and to re-evaluate the attainment of treatment goals in those with already known risk factors. Each physician enrolled up to 20 consecutive patients with hypertension and/or hyperlipidemia, a total of 3015 patients were included (52% men, 48% women, average age 61 years). CVR was assessed using the SCORE system.
Risk factors were treated in accordance with current national guidelines. The therapy of hyperlipidemia and hypertension was preferentially based on rosuvastatin, amlodipine and valsartan, further medication was in the competence of attending physician. Risk factors and CVR was assessed at baseline and after 3 and 6 months.
Results: The principal result is that the global CVR (SCORE) decreased in first control of 21% and in final control of 35%.
Systolic BD decreased of 12,5% (152±17,9 to 133±11,1), diastolic BP decreased of o 11,4% . The level of total cholesterol decreased of 21% and the concentration of LDL-C decreased of 28% (3,9±1,1 to 2,8±0,8). HDL-C increased of 7% and triglycerides decreased of 25%. All differences were statistically significant. Positive changes were reached also in glycaemia, heart rate, BMI and waist circumference. Target levels of BP were reached in almost 70% of patients. Despite the positive changes in LDL-C, only 35% patients reached the target levels of LDL-c.
Conclusion: The VARO study demonstrates that in the daily practice settings, both individual risk factors and global CVR may be significantly improved through systematic identification of high-risk individuals and treating in accordance with current guidelines using a modern pharmacotherapy.
- © 2013 by American Heart Association, Inc.